Navigation Links
MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
Date:8/19/2007

Three Independent Clinical Trials Initiated with Teplizumab Manufactured at

MacroGenics

ROCKVILLE, Md., Aug. 2 /PRNewswire/ -- MacroGenics, Inc. announced today that its Protege trial is actively enrolling adults and children ages 8 to 35 with recent-onset type 1 diabetes. The global Phase 2/3 clinical trial will evaluate the safety and efficacy of three teplizumab dosing regimens administered at the start of the study and again at six months in individuals who are up to 12 weeks from their diagnosis of type 1 diabetes. "The initiation of the pivotal Protege study is an important milestone for MacroGenics and for the type 1 diabetes research community," stated Dr. Scott Koenig, President and CEO of MacroGenics. "It is also notable that teplizumab is the first CD3 monoclonal therapy targeting type 1 diabetes to reach this stage of clinical development."

Specifically, the Protege study will assess the ability of teplizumab to inhibit the autoimmune attack that destroys insulin-producing pancreatic beta cells in individuals with type 1 diabetes. If teplizumab is effective and has the ability to preserve or protect beta cells of the pancreas, patients may require less injected insulin and their blood glucose levels may be easier to control. Other research has shown that greater control of blood glucose levels can lead to better long-term health outcomes for patients with type 1 diabetes.

Dr. Koenig also commented, "We are pleased to announce that Dr. Kevan Herold of Yale University and Dr. Bernhard Hering of the University of Minnesota are leading additional teplizumab studies in type 1 diabetes." The AbATE and Delay studies, led by Dr. Herold, are evaluating the safety and efficacy of teplizumab in patients who have had the disease for up to one year. Dr. Hering is evaluating the use of teplizumab as an induction therapy in pancreatic islet cell transplantation.

Additional information regarding the studies i
'/>"/>

SOURCE MacroGenics, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
2. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
3. New Study Reveals Limitations of a Complex and Challenging Global Tuberculosis Drug Marketplace
4. Global Rabies Treatment May be Possible with NanoViricides Drugs
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... , April 16, 2015 Mindray ... developer, manufacturer, and marketer of medical devices worldwide, ... Securities and Exchange Commission an Annual Report on Form ... year ended December 31, 2014. An electronic version of ... on Mindray,s investor relations website at  http://ir.mindray.com  or  ...
(Date:4/16/2015)... April 16, 2015  Hologic, Inc. (NASDAQ: ... screening study i published on-line this week ... of the American Cancer Society. The ... of Pittsburgh Medical Center, supports current consensus guidelines ii ... women 30-65 years of age be co-tested with ...
(Date:4/16/2015)... 16, 2015  Amgen (NASDAQ: AMGN ) today ... results on Tuesday, April 21, 2015, after the close ... followed by a conference call with the investment community ... Amgen will be Robert A. Bradway , chairman ... senior management team. Live audio of the ...
Breaking Medicine Technology:Mindray Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission 2Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 2Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 3Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 4Amgen Announces Webcast Of 2015 First Quarter Financial Results 2
... UBM Conferences , a division of UBM Plc ... Extractables and Leachables Webinar to be hosted on May ... to attend webinar will evaluate the considerations to be ... development, in addition to highlighting how monomers and additives, ...
... ARBOR, Mich., May 16, 2012  Rubicon Genomics, Inc., ... sample-specific pre-analytical processes to improve the performance and ... research and clinical testing, today announced the launch ... family of sample preparation kits designed and optimized ...
Cached Medicine Technology:Global Webinar Focuses on Considerations for Extractables and Leachables 2Rubicon Genomics Launches ThruPLEX™ Family of Sample Preparation Products for Next Generation Sequencing Applications 2Rubicon Genomics Launches ThruPLEX™ Family of Sample Preparation Products for Next Generation Sequencing Applications 3
(Date:4/17/2015)... At the end of February 2015, Choices ... to the Oscars” in the Stardust Penthouse on the ... impressive Los Angeles skyline. These events honoring the 2015 ... leading producer of sustainable product placement in TV and ... providers of eco-friendly and socially conscious products and services, ...
(Date:4/17/2015)... Organic Valley, the nation’s largest cooperative of ... Year of Soils by “Cycling for Sustainability” through California ... will travel 215 miles from Auburn, California, to the ... the impact of agriculture on water and soil in ... Wisconsin, Oregon, and Washington state, the cyclists have diverse ...
(Date:4/17/2015)... Calvary Hospital recently announced Timothy P. Barr ... President on May 11. The Fund directs all fundraising efforts ... succeeds Vincent J. Spinelli, who retired several months ago. , ... and supervise the important work that the Fund does every ... continues to expand and bring our signature care to people ...
(Date:4/17/2015)... Lowcostcarinsuranceprice.com has released a new blog post explaining the ... car insurance rates . , Falling asleep at ... have a big impact on auto insurance prices. The premiums ... claimed benefits. The newly released blog post talks more about ... , It is now possible to find low cost ...
(Date:4/17/2015)... Wholelifelifeinsurance.org has released a new blog post ... policies . , Whole life insurance can help ... families at the same time. Whole life insurance is ... customized to it the client’s needs. , Whole ... some appropriate steps.Comparing life insurance quotes is very important ...
Breaking Medicine News(10 mins):Health News:Choices Recovery Speaks with Dakota Hood of “The Hunger Games” about Addiction in Hollywood 2Health News:Organic Valley Farmers and Employees "Cycling for Sustainability" Through 215 Miles of California Watershed April 19-25 2Health News:Organic Valley Farmers and Employees "Cycling for Sustainability" Through 215 Miles of California Watershed April 19-25 3Health News:Timothy P. Barr Appointed Executive Vice President of Calvary Fund 2Health News:Timothy P. Barr Appointed Executive Vice President of Calvary Fund 3Health News:Accidents Caused By Sleeping at The Wheel Can Increase Auto Insurance Costs 2Health News:Whole Life Insurance Policies At Affordable Prices By Comparing Quotes 2
... 21 The Hispanic got milk? Milk Mustache Mobile,Drink Well. ... tour, including,the top 10 Hispanic cities, to reintroduce Hispanics to ... cruised through Denver,hosting free events to encourage local residents to ... drink -- milk. , At the ...
... are government agencies and media -- , FLEMINGTON, N.J., ... among 688 physicians revealed that over the past few ... impact that the H1N1 swine flu will have on ... )The study was conducted last night ...
... fewer signs of condition , , THURSDAY, May 21 (HealthDay News) ... has been identified by U.S. researchers, who said their finding ... , The researchers found that mice without the ion channel ... to normal mice, those lacking the gene for TRPA1 had ...
... HILLS, N.J., May 21 The Christopher & ... to finding cures and treatments for spinal cord ... with paralysis, announced today it has received a ... arm, the TD Charitable Foundation. The donation ...
... Sensors for Medicine and Science, Inc., a ... could dramatically improve continuous glucose monitoring for people ... $10 million financing with a strategic investor. ... existing Series C preferred stock. No product ...
... Gulf Coast Medical Center,s Average ER Wait TimePANAMA CITY, Fla., ... Panama City, FL area to find out the average ER ... to the hospital. The hospital is posting its average ... this year, we became the only hospital in our area ...
Cached Medicine News:Health News:The Hispanic got milk? Campaign Visited Denver May 17th - May 20th 2Health News:Physicians are Less Concerned about H1N1 Swine Flu 2Health News:Physicians are Less Concerned about H1N1 Swine Flu 3Health News:Physicians are Less Concerned about H1N1 Swine Flu 4Health News:Christopher & Dana Reeve Foundation Receives $25,000 Gift from TD Bank 2Health News:Christopher & Dana Reeve Foundation Receives $25,000 Gift from TD Bank 3Health News:ER Wait Times at Your Fingertips 2
... for Unparalleled Comfort Pick one of our ... Notice the trigger and ejector positionsright where they ... pipettors are ergonomically designed to help avoid repetitive ... Productivity In The Palm Of Your Hand ...
... Ergonomic Design for Unparalleled Comfort ... it. Notice the balance. Notice the trigger and ... left-handed. Thats because our pipettors are ergonomically designed ... long hours of pipetting. Productivity In The ...
... ergonomic solution and best value in high ... action and ultra lightweight design reduce hand ... with long, lever tip ejector , Color ... universal tips or for greater performance use ...
... Finnpipette BioControl multichannel has ... as the single channel ... fits allseven multichannel and ... cone modules. Both pipettes ...
Medicine Products: